Siga Technologies, Inc.
CAGE Code: 1V4X4
NCAGE Code: 1V4X4
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 932651516
Summary
Siga Technologies, Inc. is an Active Manufacturer with the Cage Code 1V4X4 and is tracked by Dun & Bradstreet under DUNS Number 932651516..
Address
31, East 62Nd Street
New York NY 10065-8014
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
Tempo Sense Inc Trumeter Co Inc Doctors Without Borders Lorrillard Tobacco Co Industrial Scientific Co Amerotron Corp Fuller George A Co Div Of Northrop Standard Industries Inc M Rosenblatt & Son Inc American Business Machines Inc Associated American Trading Div Of Syrkus And Guttman Inc Rhi Entertainment Inc A B C Inc Play Co Toys Inc Buttling Padgett Co Inc Mutual Electric And Machine Corp Vulcan Machine And Mfg Inc Anchor Steel Co National Ignition Mfg Co Inc
Frequently Asked Questions (FAQ) for CAGE 1V4X4
- What is CAGE Code 1V4X4?
- 1V4X4 is the unique identifier used by NATO Organizations to reference the physical entity known as Siga Technologies, Inc. located at 31, East 62Nd Street, New York NY 10065-8014, United States.
- Who is CAGE Code 1V4X4?
- 1V4X4 refers to Siga Technologies, Inc. located at 31, East 62Nd Street, New York NY 10065-8014, United States.
- Where is CAGE Code 1V4X4 Located?
- CAGE Code 1V4X4 is located in New York, NY, USA.
- How Many NSNs Does CAGE Code 1V4X4 Supply?
- CAGE Code 1V4X4 has been assigned as an approved source for 1 NSNs (National Stock Numbers and NATO Stock Numbers).
Contracting History for CAGE 1V4X4 Most Recent 25 Records
- W911SR22C0051
- Tpoxx Course (Option)
- 30 Mar 2023
- Tpoxx Course (Option)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $10,660,619.54
- Department Of Defense (Dod)
- W911SR22C0051
- Tpoxx Course (Base)
- 27 Jan 2023
- Tpoxx Course (Base)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $10,660,619.54
- Department Of Defense (Dod)
- W911SR22C0032
- Exercise Optional Clins 0002 And 0004 To Procure Additional Doses (10,885) Of Tpoxx (Smallpox Antiviral Therapeutic And Shipping.
- 25 Aug 2022
- Exercise Optional Clins 0002 And 0004 To Procure Additional Doses (10,885) Of Tpoxx (Smallpox Antiviral Therapeutic And Shipping.
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $7,469,637.50
- Department Of Defense (Dod)
- HHSO100201100001C
- Purpose: This Modification Is To Exercise Option Clin 0011, B.5. Price Schedule, Payment For Fda Approval For Extension To 84-Month Expiry Product, As Described In Section C.7.1 (Nsp). Funds Alloted Prior To Mod #15 $472,320,688.00 Funds Allotted With Mod #15 $ 50,000,000.00 Total Funds Alloted To Date $522,320,688.00 Changed) Expiration Date: September 24, 2020 (Unchanged) Contract Funded Through September 24, 2020 (Unchanged) Total Contract Value Is Changed From Not To Exceed $472,320,688.00 By $50,000,000.00 To $522,320,688.00.
- 30 Jul 2018
- Purpose: This Modification Is To Exercise Option Clin 0011, B.5. Price Schedule, Payment For Fda Approval For Extension To 84-Month Expiry Product, As Described In Section C.7.1 (Nsp). Funds Alloted Prior To Mod #15 $472,320,688.00 Funds Allotted With Mod #15 $ 50,000,000.00 Total Funds Alloted To Date $522,320,688.00 Changed) Expiration Date: September 24, 2020 (Unchanged) Contract Funded Through September 24, 2020 (Unchanged) Total Contract Value Is Changed From Not To Exceed $472,320,688.00 By $50,000,000.00 To $522,320,688.00.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $522,320,688.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf The Purpose Of This Modification Is To (1) Exercise Option Clin0009a In The Amount Of $11,255,170.00, (2) Modify Article G.2. To Change The Contracting Officer's Representative As Follows; (3) Revise Article B.3. To Breakout Clin0009 Into Four Subparts (0009A, 0009B, 0009C, 0009D) As Follows. All Other Terms And Conditions In The Contract Remain Unchanged.
- 20 May 2019
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf The Purpose Of This Modification Is To (1) Exercise Option Clin0009a In The Amount Of $11,255,170.00, (2) Modify Article G.2. To Change The Contracting Officer's Representative As Follows; (3) Revise Article B.3. To Breakout Clin0009 Into Four Subparts (0009A, 0009B, 0009C, 0009D) As Follows. All Other Terms And Conditions In The Contract Remain Unchanged.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $75,083,950.00
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- The Purpose Of Modification 20 Is To Reconcile Funds Between Siga And Barda, Update Coa Threshold, Make Minor Adjustment To The Statement Of Work, Change Co And Cor.
- 16 Nov 2019
- The Purpose Of Modification 20 Is To Reconcile Funds Between Siga And Barda, Update Coa Threshold, Make Minor Adjustment To The Statement Of Work, Change Co And Cor.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- HHSO100201100001C
- No-Cost Supplemental Agreement To Incorporate By Executive Order 14042 - Far Deviation Clause 52.223-99, Ensuring Adequate Covid Safety Protocols For Federal Contractors. No Other Changes Apply.
- 4 Nov 2021
- No-Cost Supplemental Agreement To Incorporate By Executive Order 14042 - Far Deviation Clause 52.223-99, Ensuring Adequate Covid Safety Protocols For Federal Contractors. No Other Changes Apply.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $518,482,778.15
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Executive Order 14042 - Far Deviation Clause 52.223-99 To Provide Adequate Covid-19 Safety Protocols For Federal Contractors.
- 1 Nov 2021
- Executive Order 14042 - Far Deviation Clause 52.223-99 To Provide Adequate Covid-19 Safety Protocols For Federal Contractors.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $291,373,355.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf
- 10 Sep 2018
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $51,641,805.00
- Department Of Health And Human Services (Hhs)
- HHSO100201100001C
- Mod To Correct Error On Mod 21
- 29 Sep 2022
- Mod To Correct Error On Mod 21
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $518,482,778.15
- Department Of Health And Human Services (Hhs)
- HHSO100201100001C
- Igf::Ot::Igf
- 27 Sep 2018
- Igf::Ot::Igf
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $518,482,778.15
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Exercise Of Option Clin 0010 For Additional Procurement Of Nonparenteral (Oral)Formulated Antiviral As Fdp And Delivery To The Sns
- 7 Sep 2021
- Exercise Of Option Clin 0010 For Additional Procurement Of Nonparenteral (Oral)Formulated Antiviral As Fdp And Delivery To The Sns
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $291,373,355.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Mod For Supplemental Funding For Clin 7 Changes To Complete Fda Required Ph Iv Post-Marketing Study Option. Change In Clin 0003&0007 Description And Related Sow. Change In Co.
- 15 Jan 2020
- Mod For Supplemental Funding For Clin 7 Changes To Complete Fda Required Ph Iv Post-Marketing Study Option. Change In Clin 0003&0007 Description And Related Sow. Change In Co.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $77,509,765.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Administrative Corrections
- 18 Oct 2023
- Administrative Corrections
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $458,763,061.00
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- Purpose:(1) Exercise The Following Five Options: Iv Option 2 (Clin #3), Iv Option 3 (Clin # 4), Iv Option 4 (Clin # 5), Iv Option 6 (Clin #7) And Iv Option 7 (Clin #8) Which Also Extends The Period Of Performance Of This Contract From June 30, 2020 To December 30, 2020.
- 8 Feb 2017
- Purpose:(1) Exercise The Following Five Options: Iv Option 2 (Clin #3), Iv Option 3 (Clin # 4), Iv Option 4 (Clin # 5), Iv Option 6 (Clin #7) And Iv Option 7 (Clin #8) Which Also Extends The Period Of Performance Of This Contract From June 30, 2020 To December 30, 2020.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- The Purpose Of This Modification Is To (1) Change The Contracting Officer To Elizabeth Steiner In Section G.1-A Contracting Officer And Mailing Address. All References To The Contracting Officer Are Updated To Reflect This Change.
- 27 Sep 2017
- The Purpose Of This Modification Is To (1) Change The Contracting Officer To Elizabeth Steiner In Section G.1-A Contracting Officer And Mailing Address. All References To The Contracting Officer Are Updated To Reflect This Change.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- Purpose: (1) To Extend The Clin 0002 Period Of Performance To Reflect A No Cost Extension (Nce) From 18Feb2018 To 30Sept2018. All References To The Pop End Date For Clin 0002 Are Updated To Reflect This Change. Total Funds Alloted To Date $37,375,485 (Unchanged) Contract Expiration Date: December 30, 2020 (Unchanged) Clin 0002 Pop 30Sept2018 (Changed) Clin 0003 Pop 30Dec2019 (Unchanged) Clin 0004 Pop 30Dec2020 (Unchanged) Clin 0005 Pop 30Dec2020 (Unchanged) Clin 0006 Pop 30June2020 (Unchanged) Clin 0007 Pop 30Dec2020 (Unchanged) Clin 0008 Pop 30Dec2020 (Unchanged) Clin 0011 Pop 28Feb2014 (Unchanged) Clin 0012 Pop 31Dec2016 (Unchanged) Clin 0013 Pop 31Dec2013 (Unchanged)
- 21 Dec 2017
- Purpose: (1) To Extend The Clin 0002 Period Of Performance To Reflect A No Cost Extension (Nce) From 18Feb2018 To 30Sept2018. All References To The Pop End Date For Clin 0002 Are Updated To Reflect This Change. Total Funds Alloted To Date $37,375,485 (Unchanged) Contract Expiration Date: December 30, 2020 (Unchanged) Clin 0002 Pop 30Sept2018 (Changed) Clin 0003 Pop 30Dec2019 (Unchanged) Clin 0004 Pop 30Dec2020 (Unchanged) Clin 0005 Pop 30Dec2020 (Unchanged) Clin 0006 Pop 30June2020 (Unchanged) Clin 0007 Pop 30Dec2020 (Unchanged) Clin 0008 Pop 30Dec2020 (Unchanged) Clin 0011 Pop 28Feb2014 (Unchanged) Clin 0012 Pop 31Dec2016 (Unchanged) Clin 0013 Pop 31Dec2013 (Unchanged)
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- Executive Order 14042 - Far Deviation Clause 52.223-99 To Provide Adequate Covid-19 Safety Protocols For Federal Contractors.
- 1 Nov 2021
- Executive Order 14042 - Far Deviation Clause 52.223-99 To Provide Adequate Covid-19 Safety Protocols For Federal Contractors.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Mod For Supplemental Funding For Clin 7 Changes To Complete Fda Required Ph Iv Post-Marketing Study Option. Change In Clin 0003&0007 Description And Related Sow. Change In Co.
- 5 Sep 2019
- Mod For Supplemental Funding For Clin 7 Changes To Complete Fda Required Ph Iv Post-Marketing Study Option. Change In Clin 0003&0007 Description And Related Sow. Change In Co.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $77,509,765.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf The Purpose Of This Modification Is To Exercise Option Clin0007 In The Amount Of $12,186,975.00 And Change The Cor Information Listed In Article G.2 As Follows.
- 21 Feb 2019
- Procurement And Late-Stage Development Of Smallpox Antiviral Drug(S) Igf::Ot::Igf The Purpose Of This Modification Is To Exercise Option Clin0007 In The Amount Of $12,186,975.00 And Change The Cor Information Listed In Article G.2 As Follows.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $63,828,780.00
- Department Of Health And Human Services (Hhs)
- HHSO100201100001C
- Purpose: This Modification Is To Adjust Funding Under Clin 0006 And Update Designated Cor And Alternate Cor.Funds Alloted Prior To Mod #16 $522,320,688.00Funds Removed With Mod #16 - $230,902.00Funds Allotted With Mod #16 + $230,902.00Total Funds Alloted To Date $522,320,688.00 (Unchanged)Expiration Date: September 24, 2020 (Unchanged) Contract Funded Through September 24, 2020 (Unchanged)1) The Following Revision Is Made To Clin 0006 Under This Modification:Clin 0006 Is Being Deobligated In Full And Then Re Obligated In Full. The Amount Of Decrease ($230,902) And Then Increase ($230,902). The Total Value Of This Ffp Clin Is $230,902.00. 2) Update Section G, Article G.2. As Follows And Replace The Designated Primary Cor:Article G.2. Contracting Officer's Representative (Cor)The Following Contracting Officer's Representative (Cor) Will Represent The Government For The Purpose Of This Contract:Claiborne Hughes Primary Cor Chia-Wei Tsai, Phd Alternate Coras Delegated By The Contracting Officer, The Cor Is Responsible For: (1) Monitoring The Contractor's Technical Progress, Including The Surveillance And Assessment Of Performance And Recommending To The Contracting Officer Changes In Requirements; (2) Assisting The Contracting Officer In Interpreting The Statement Of Work And Any Other Technical Performance Requirements; (3) Performing Technical Evaluation As Required; (4) Performing Technical Inspections And Acceptances Required By This Contract; And (5) Assisting In The Resolution Of Technical Problems Encountered During Performance.All Other Terms And Conditions Of Contract Hhso100201100001c Remain Unchanged.
- 19 Sep 2018
- Purpose: This Modification Is To Adjust Funding Under Clin 0006 And Update Designated Cor And Alternate Cor.Funds Alloted Prior To Mod #16 $522,320,688.00Funds Removed With Mod #16 - $230,902.00Funds Allotted With Mod #16 + $230,902.00Total Funds Alloted To Date $522,320,688.00 (Unchanged)Expiration Date: September 24, 2020 (Unchanged) Contract Funded Through September 24, 2020 (Unchanged)1) The Following Revision Is Made To Clin 0006 Under This Modification:Clin 0006 Is Being Deobligated In Full And Then Re Obligated In Full. The Amount Of Decrease ($230,902) And Then Increase ($230,902). The Total Value Of This Ffp Clin Is $230,902.00. 2) Update Section G, Article G.2. As Follows And Replace The Designated Primary Cor:Article G.2. Contracting Officer's Representative (Cor)The Following Contracting Officer's Representative (Cor) Will Represent The Government For The Purpose Of This Contract:Claiborne Hughes Primary Cor Chia-Wei Tsai, Phd Alternate Coras Delegated By The Contracting Officer, The Cor Is Responsible For: (1) Monitoring The Contractor's Technical Progress, Including The Surveillance And Assessment Of Performance And Recommending To The Contracting Officer Changes In Requirements; (2) Assisting The Contracting Officer In Interpreting The Statement Of Work And Any Other Technical Performance Requirements; (3) Performing Technical Evaluation As Required; (4) Performing Technical Inspections And Acceptances Required By This Contract; And (5) Assisting In The Resolution Of Technical Problems Encountered During Performance.All Other Terms And Conditions Of Contract Hhso100201100001c Remain Unchanged.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $518,482,778.15
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- Mod 21 Provides A Ncte For Clin 3, 4, 5, And 7 And Supplemental Funds To Finalize Clin 6. Change Co And Cor.
- 2 Jul 2020
- Mod 21 Provides A Ncte For Clin 3, 4, 5, And 7 And Supplemental Funds To Finalize Clin 6. Change Co And Cor.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- HHSN272200800041C
- Mod Provides Supplemental Funding In Support Of Indirect Rate Redetermination On Ar&D Contract.
- 3 Feb 2022
- Mod Provides Supplemental Funding In Support Of Indirect Rate Redetermination On Ar&D Contract.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,272,195.89
- Department Of Health And Human Services (Hhs)
- 75A50118C00019
- Admin No-Cost Mod 9 Extends Cx Line Items 7 & 8 Delivery Date To 3/31/2022 And Clarifies Contract's Full Term End Date Of 9/9/2028.
- 27 Jan 2022
- Admin No-Cost Mod 9 Extends Cx Line Items 7 & 8 Delivery Date To 3/31/2022 And Clarifies Contract's Full Term End Date Of 9/9/2028.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $291,373,355.00
- Department Of Health And Human Services (Hhs)
- HHSO100201100001C
- Deobligation Mod
- 22 Sep 2022
- Deobligation Mod
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $515,864,484.61
- Department Of Health And Human Services (Hhs)
Supply Items Approved for CAGE 1V4X4 Page 1 of 1
- NDC50072-0200-42
- RNCC: 3 | RNVC: 2 | DAC: 4